Esomeprazole & Naproxen

Esomeprazole & Naproxen

IPR decision: Sep 06, 2019
AIA Review #
Filing Date
Institution Decision Date
Petitioner
Patent
Respondent
Status
IPR2018-00272
12/04/2017
06/14/2018
Mylan Pharmaceuticals Inc.*/ DRL
9,393,208
Horizon Pharma
Claims 1–7 unpatentable
* PTAB terminated the proceeding between Petitioner Mylan  Pharmaceuticals Inc. and Patent Owners by Order on August 12, 2019. Petitioner Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”) from IPR2018-1341 was joined as Petitioner to this proceeding on April 1, 2019. Dr. Reddy’s remains as a Petitioner in this case.
US 9,393,208 (Pozen Inc./ Horizon Pharma USA, Inc.; Exp: 09/03/2029) – OB listed
1. A method for delivering a pharmaceutical composition to a patient in need thereof, comprising: orally administering to the patient an AM unit dose form and, 10 hours (.+-.20%) later, a PM unit dose form, wherein: the AM and PM unit dose forms each comprises: i) naproxen, or a pharmaceutically acceptable salt thereof, in an amount to provide 500 mg of naproxen, and ii) esomeprazole, or a pharmaceutically acceptable salt thereof, in an amount to provide 20 mg of esomeprazole; said esomeprazole, or pharmaceutically acceptable salt thereof, is released from said AM and PM unit dose forms at a pH of 0 or greater, the AM and PM unit dose forms target: i) a pharmacokinetic (pk) profile for naproxen where: a) for the AM dose of naproxen, the mean C.sub.max is 86.2 .mu.g/mL (.+-.20%) and the median T.sub.max is 3.0 hours (.+-.20%); and b) for the PM dose of naproxen, the mean C.sub.max is 76.8 .mu.g/mL (.+-.20%) and the median T.sub.max is 10 hours (.+-.20%); and ii) a pharmacokinetic (pk) profile for esomeprazole where: a) for the AM dose of esomeprazole, the mean area under the plasma concentration-time curve from when the AM dose is administered to 10 hours (.+-.20%) after the AM dose is administered (AUC0-10,am) is 1216 hr*ng/mL (.+-.20%), b) for the PM dose of esomeprazole, the mean area under the plasma concentration-time curve from when the PM dose is administered to 14 hours (.+-.20%) after the PM dose is administered (AUC0-14,pm) is 919 hr*ng/mL (.+-.20%), and c) the total mean area under the plasma concentration-time curve for esomeprazole from when the AM dose is administered to 24 hours (.+-.20%) after the AM dose is administered (AUC0-24) is 2000 hr*ng/mL (.+-.20%); and the AM and PM unit dose forms further target a mean % time at which intragastric pH remains at about 4.0 or greater for about a 24 hour period after reaching steady state that is at least about 60%.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved